Avience Biomedicals IPO: Price Band, GMP, and Key Investment Details

Noida-based molecular diagnostics manufacturer Avience Biomedicals is set to launch its highly anticipated IPO this Thursday. With strong pre-listing demand reflected in the grey market, investors are closely monitoring this SME issue as it seeks to fund its next phase of manufacturing expansion.

IPO Pricing, Timeline, and Grey Market Buzz

The Avience Biomedicals IPO is priced in a band of Rs 196 to Rs 208 per share. The subscription window opens this Thursday and will remain active until June 22. Investors can expect the allotment process to be completed by June 23, with the company slated to list on the NSE SME platform on June 25.

Market sentiment appears bullish, as the Grey Market Premium (GMP) stands at approximately 36% ahead of the opening. This implies an unofficial market price of around Rs 283, representing a premium of roughly Rs 75 per share over the upper price band. This robust GMP signals strong investor appetite, setting it apart from other SME issues that have seen muted activity this week.

Issue Structure and Allocation Details

The total issue size is Rs 30.24 crore, consisting entirely of a fresh issue of 14,53,800 shares. Notably, there is no Offer-for-Sale (OFS) component, ensuring that the entire proceeds will be directed toward the company's growth initiatives. Out of the total issue, 13,71,600 shares are available to the public after reserving 82,200 shares for the market maker, Asnani Stock Broker.

The allocation is structured to favor institutional participation:

For retail investors, the lot size is fixed at 600 shares, requiring a minimum investment of Rs 1,24,800 at the upper price band. High-Net-Worth Individuals (HNIs) must apply for a minimum of 3 lots (1,800 shares), totaling approximately Rs 3,74,400.

Business Model and Financial Performance

Avience Biomedicals is an ISO-certified manufacturer specializing in molecular diagnostic solutions, biotechnology, and genomics. Their product portfolio is diverse, ranging from rapid test kits for dengue and malaria to biochemistry analysers and medical devices like oxygen concentrators. The company operates a B2B and B2G model, serving hospitals, pathology labs, and research centers both in India and internationally.

The company has demonstrated significant financial momentum. Revenue surged from Rs 24.37 crore in FY24 to Rs 45.97 crore in FY25. Even more impressive is the bottom-line growth, with Profit After Tax (PAT) jumping from Rs 2.14 crore in FY24 to Rs 7.23 crore in FY25. For the ten months ending January 2026, the company reported a total income of Rs 41.94 crore and a PAT of Rs 5.74 crore.

Utilization of Proceeds

The company intends to utilize the fresh capital to bolster its manufacturing capabilities. Approximately Rs 15.96 crore is earmarked for capital expenditure to set up a new manufacturing unit at the Medical Device Park under the Yamuna Expressway Industrial Development Authority in Gautam Buddha Nagar, Uttar Pradesh. An additional Rs 8.25 crore will be deployed to meet working capital requirements.

Key Takeaways